These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 29146411)

  • 1. Metabolic adaptation to intermittent fasting is independent of peroxisome proliferator-activated receptor alpha.
    Li G; Brocker CN; Yan T; Xie C; Krausz KW; Xiang R; Gonzalez FJ
    Mol Metab; 2018 Jan; 7():80-89. PubMed ID: 29146411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transgenic expression of mutant peroxisome proliferator-activated receptor gamma in liver precipitates fasting-induced steatosis but protects against high-fat diet-induced steatosis in mice.
    Tanaka T; Masuzaki H; Ebihara K; Ogawa Y; Yasue S; Yukioka H; Chusho H; Miyanaga F; Miyazawa T; Fujimoto M; Kusakabe T; Kobayashi N; Hayashi T; Hosoda K; Nakao K
    Metabolism; 2005 Nov; 54(11):1490-8. PubMed ID: 16253638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extrahepatic PPARα modulates fatty acid oxidation and attenuates fasting-induced hepatosteatosis in mice.
    Brocker CN; Patel DP; Velenosi TJ; Kim D; Yan T; Yue J; Li G; Krausz KW; Gonzalez FJ
    J Lipid Res; 2018 Nov; 59(11):2140-2152. PubMed ID: 30158201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PPARα protects against trans-fatty-acid-containing diet-induced steatohepatitis.
    Hu X; Tanaka N; Guo R; Lu Y; Nakajima T; Gonzalez FJ; Aoyama T
    J Nutr Biochem; 2017 Jan; 39():77-85. PubMed ID: 27816763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diminished Hepatocarcinogenesis by a Potent, High-Affinity Human PPARα Agonist in PPARA-Humanized Mice.
    Foreman JE; Koga T; Kosyk O; Kang BH; Zhu X; Cohen SM; Billy LJ; Sharma AK; Amin S; Gonzalez FJ; Rusyn I; Peters JM
    Toxicol Sci; 2021 Aug; 183(1):70-80. PubMed ID: 34081128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
    Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
    J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic ATF6 Increases Fatty Acid Oxidation to Attenuate Hepatic Steatosis in Mice Through Peroxisome Proliferator-Activated Receptor α.
    Chen X; Zhang F; Gong Q; Cui A; Zhuo S; Hu Z; Han Y; Gao J; Sun Y; Liu Z; Yang Z; Le Y; Gao X; Dong LQ; Gao X; Li Y
    Diabetes; 2016 Jul; 65(7):1904-15. PubMed ID: 27207533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of peroxisome proliferator-activated receptor-alpha in fasting-mediated oxidative stress.
    Abdelmegeed MA; Moon KH; Hardwick JP; Gonzalez FJ; Song BJ
    Free Radic Biol Med; 2009 Sep; 47(6):767-78. PubMed ID: 19539749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice.
    Tanaka N; Moriya K; Kiyosawa K; Koike K; Gonzalez FJ; Aoyama T
    J Clin Invest; 2008 Feb; 118(2):683-94. PubMed ID: 18188449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic PPARα is critical in the metabolic adaptation to sepsis.
    Paumelle R; Haas JT; Hennuyer N; Baugé E; Deleye Y; Mesotten D; Langouche L; Vanhoutte J; Cudejko C; Wouters K; Hannou SA; Legry V; Lancel S; Lalloyer F; Polizzi A; Smati S; Gourdy P; Vallez E; Bouchaert E; Derudas B; Dehondt H; Gheeraert C; Fleury S; Tailleux A; Montagner A; Wahli W; Van Den Berghe G; Guillou H; Dombrowicz D; Staels B
    J Hepatol; 2019 May; 70(5):963-973. PubMed ID: 30677458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocyte peroxisome proliferator-activated receptor α regulates bile acid synthesis and transport.
    Xie C; Takahashi S; Brocker CN; He S; Chen L; Xie G; Jang K; Gao X; Krausz KW; Qu A; Levi M; Gonzalez FJ
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1396-1411. PubMed ID: 31195146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic peroxisome proliferator-activated receptor alpha mediates the major metabolic effects of Wy-14643.
    Li G; Brocker CN; Xie C; Yan T; Noguchi A; Krausz KW; Xiang R; Gonzalez FJ
    J Gastroenterol Hepatol; 2018 May; 33(5):1138-1145. PubMed ID: 29141109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of fatty acid and bile acid metabolism by peroxisome proliferator-activated receptor α protects against alcoholic liver disease.
    Li HH; Tyburski JB; Wang YW; Strawn S; Moon BH; Kallakury BV; Gonzalez FJ; Fornace AJ
    Alcohol Clin Exp Res; 2014 Jun; 38(6):1520-31. PubMed ID: 24773203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eicosapentaenoic acid improves hepatic steatosis independent of PPARα activation through inhibition of SREBP-1 maturation in mice.
    Tanaka N; Zhang X; Sugiyama E; Kono H; Horiuchi A; Nakajima T; Kanbe H; Tanaka E; Gonzalez FJ; Aoyama T
    Biochem Pharmacol; 2010 Nov; 80(10):1601-12. PubMed ID: 20691165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CBFA2T3 Is PPARA Sensitive and Attenuates Fasting-Induced Lipid Accumulation in Mouse Liver.
    Kim D; Ha SK; Gonzalez FJ
    Cells; 2024 May; 13(10):. PubMed ID: 38786053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonhematopoietic Peroxisome Proliferator-Activated Receptor-α Protects Against Cardiac Injury and Enhances Survival in Experimental Polymicrobial Sepsis.
    Standage SW; Waworuntu RL; Delaney MA; Maskal SM; Bennion BG; Duffield JS; Parks WC; Liles WC; McGuire JK
    Crit Care Med; 2016 Aug; 44(8):e594-603. PubMed ID: 26757163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Species Differences between Mouse and Human PPARα in Modulating the Hepatocarcinogenic Effects of Perinatal Exposure to a High-Affinity Human PPARα Agonist in Mice.
    Foreman JE; Koga T; Kosyk O; Kang BH; Zhu X; Cohen SM; Billy LJ; Sharma AK; Amin S; Gonzalez FJ; Rusyn I; Peters JM
    Toxicol Sci; 2021 Aug; 183(1):81-92. PubMed ID: 34081146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 5:2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPARα and PCK1.
    Gallage S; Ali A; Barragan Avila JE; Seymen N; Ramadori P; Joerke V; Zizmare L; Aicher D; Gopalsamy IK; Fong W; Kosla J; Focaccia E; Li X; Yousuf S; Sijmonsma T; Rahbari M; Kommoss KS; Billeter A; Prokosch S; Rothermel U; Mueller F; Hetzer J; Heide D; Schinkel B; Machauer T; Pichler B; Malek NP; Longerich T; Roth S; Rose AJ; Schwenck J; Trautwein C; Karimi MM; Heikenwalder M
    Cell Metab; 2024 Jun; 36(6):1371-1393.e7. PubMed ID: 38718791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic ablation of solute carrier family 7a3a leads to hepatic steatosis in zebrafish during fasting.
    Gu Q; Yang X; Lin L; Li S; Li Q; Zhong S; Peng J; Cui Z
    Hepatology; 2014 Dec; 60(6):1929-41. PubMed ID: 25130427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Periostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARα.
    Lu Y; Liu X; Jiao Y; Xiong X; Wang E; Wang X; Zhang Z; Zhang H; Pan L; Guan Y; Cai D; Ning G; Li X
    J Clin Invest; 2014 Aug; 124(8):3501-13. PubMed ID: 25003192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.